Characteristics of Patients with Type 2 Diabetes Mellitus Receiving Treatment with Dapagliflozin Versus Sitagliptin: An Analysis of Commercial Claims and Linked Laboratory Data

Trial Identifier:	D1690R00034
Sponsor:	AstraZeneca
Collaborator:	Optum
NCTID::	NCT03078049
Start Date:	March 2017
Primary Completion Date:	April 2017
Condition:	Diabetes: Type 2

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Stay informed about new Trial Results Summaries with our email notification service

Trial Locations

Country	Location
USA, DE	Wilmington, DE, USA, 19803

Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered office is 3 More London Riverside, London SE1 2AQ.